bioGenous BIOTECH, Inc

bioGenous BIOTECH, Inc. was established in March 2021 and completed a corporate restructuring in September 2022, with its headquarters located in Suzhou Industrial Park. The company is dedicated to providing standardized organoid products and integrated technical services, covering three key application areas: basic research, precision medicine, and drug development. The founding team has deeply engaged in technological innovation within the organoid industry, having developed the world's first human organoid COVID-19 infection model, a medulloblastoma model, and various other disease models and drug development platforms. They also created the first international organoid scenario device and an AI drug screening platform, along with an innovative organoid model construction platform based on tissue and tumor microenvironment analysis. bioGenous offers a full range of reagents and kits for multi-lineage and multi-cancer organoids, as well as whole-process CDMO and CRO technical services. The company upholds the vision of "Landscape of human organoids, Ideal model in clinics and research" focusing on top-tier R&D talent as its core and aiming to be "the global leading organoid model platform." It is committed to providing high-quality and efficient services to significantly enhance clients' drug development efficiency and basic research capabilities, ensuring that effective medications reach the public sooner.